Patents by Inventor Robert Shorr

Robert Shorr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210000850
    Abstract: Compositions for the treatment, prevention of, proliferation of, or killing of cells associated with metastatic progression of cancer in a cancer patient are disclosed. More specifically, compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. Compositions disclosed herein include formulations of monolaurin, and formulations including monolaurin and additional components. Also, methods of treating metastatic cancer and/or preventing cancer relapse in a cancer patient by administering compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed.
    Type: Application
    Filed: July 3, 2020
    Publication date: January 7, 2021
    Inventors: Robert Shorr, Jeffrey Schwartz
  • Publication number: 20200331931
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty, acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 22, 2020
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Patent number: 10526357
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: January 7, 2020
    Assignee: Rafael Pharmaceuticals, Inc.
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Patent number: 10450337
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 22, 2019
    Assignee: Rafael Pharmaceuticals, Inc.
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Publication number: 20190119309
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 25, 2019
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Patent number: 10179796
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: January 15, 2019
    Assignee: Rafael Pharmaceuticals, Inc.
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Publication number: 20180273551
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty, acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Application
    Filed: February 19, 2018
    Publication date: September 27, 2018
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Publication number: 20170354640
    Abstract: The disclosure provides thiol-containing alkyl fatty acid and vitamin D compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are useful for treating metabolic dysfunctions such as pre-diabetes, Metabolic Syndrome and diabetes. Also provided are methods of treatment comprising the daily administration of the disclosed thiolcontaining alkyl fatty acid formulations alone or in combination with the disclosed vitamin D compound formulations.
    Type: Application
    Filed: October 26, 2015
    Publication date: December 14, 2017
    Inventor: Robert Shorr
  • Publication number: 20170217998
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Publication number: 20170218003
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Publication number: 20150322103
    Abstract: Therapeutically-effective amounts of novel analogs or derivatives of alkyl fatty, acids, such as but not limited to lipoic acid, and pharmaceutical formulations comprising such analogs or derivatives and pharmaceutically-acceptable carriers therefor, are useful for the treatment, prevention, imaging, and/or diagnosis of medical disorders.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 12, 2015
    Applicant: CORNERSTONE PHARMACEUTICALS, INC.
    Inventors: Robert Shorr, Robert Rodriguez, Paul Bingham, Lakmal Boteju, Thomas Kwok, James Marecek
  • Patent number: 7521066
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: April 21, 2009
    Assignee: Cornerstone Pharmaceuticals
    Inventors: Robert Shorr, Robert Rodriguez
  • Patent number: 7387790
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: June 17, 2008
    Assignee: Cornerstone Pharmaceuticals
    Inventors: Robert Shorr, Robert Rodriguez
  • Publication number: 20070203166
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Application
    Filed: April 30, 2007
    Publication date: August 30, 2007
    Inventors: Robert Shorr, Robert Rodriguez
  • Publication number: 20070178435
    Abstract: The present invention is directed to methods of preserving mammalian heart, ex vivo. Nanoparticle compositions for carrying out the invention are also disclosed.
    Type: Application
    Filed: March 22, 2007
    Publication date: August 2, 2007
    Applicant: Lifeblood Medical, Inc.
    Inventors: Joseph Fischer, Jan Baker, Robert Shorr
  • Patent number: 7220428
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Grant
    Filed: October 27, 2004
    Date of Patent: May 22, 2007
    Assignee: Cornerstone Pharmaceuticals
    Inventors: Robert Shorr, Robert Rodriguez
  • Publication number: 20050112207
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Application
    Filed: October 27, 2004
    Publication date: May 26, 2005
    Inventors: Robert Shorr, Robert Rodriguez
  • Publication number: 20050048064
    Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
    Type: Application
    Filed: August 2, 2004
    Publication date: March 3, 2005
    Inventors: Marc Whitlow, Robert Shorr, David Filpula, Lihsyng Lee
  • Publication number: 20050037330
    Abstract: The present invention is directed to nanoparticle compositions for maintaining organ, tissue and cellular viability when such are separated from normal physiological supports. Compositions containing the nanoparticle compositions and methods of preserving organs such as kidneys, both in vivo and ex vivo, are also disclosed.
    Type: Application
    Filed: May 7, 2004
    Publication date: February 17, 2005
    Inventors: Joseph Fischer, Jan Baker, Robert Shorr
  • Publication number: 20050008650
    Abstract: The present invention relates to the chemical modification of single chain polypeptides by means of covalent attachment of strands of poly(ethylene glycol) PEG and similar poly(alkylene oxides) to single chain polypeptide binding molecules that have the three dimensional folding and, thus, the binding ability and specificity, of the variable region of an antibody. Such preparations of modified single chain polypeptide binding molecules have reduced immugenicity and antigenicity as well as having a longer halflife in the bloodstream as compared to the parent polypeptide. These beneficial properties of the modified single chain polypeptide binding molecules make them very useful in a variety of therapeutic applications. The invention also relates to multivalent antigen-binding molecules capable of PEGylation. Compositions of, genetic constructions for, methods of use, and methods for producing PEGylated antigen-binding proteins are disclosed.
    Type: Application
    Filed: August 10, 2004
    Publication date: January 13, 2005
    Inventors: Marc Whitlow, Robert Shorr, David Filpula, Lihsyng Lee